LIFE SCIENCES FORUM 2019
SEPTEMBER 18
CONVENE 810 SEVENTH AVE, NEW YORK

FREE FOR IN-HOUSE COUNSEL

SPONSORS

Dechert LLP  Finnegan  Gorodissky  Gowlings WLG  Rell & Manella LLP
Marks & Clerk  Ropes & Gray  Sterne Kessler Goldstein & Fox  Weil

#MIPLIFESCIENCES
WWW.MANAGINGIP.COM/LIFESCIENCES

REGISTRATIONS
registrations@managingip.com
+44 (0) 207 779 8938

PROGRAMME
raf.oreilly@legalmediagroup.com

SPONSORSHIP
mpetch@euromoneyplc.com
+44 (0) 207 779 8836
While AbbVie Inc. and Boehringer Ingelheim GmbH may well have finally settled their biosimilar dispute in relation to Humira, the world’s bestselling drug with $20 billion in global sales in 2018, the FDA’s recent approval of Samsung Bioepis’s Etcovo biosimilar was at the same time closely followed by the almost immediate launch of litigation by Amgen in response.

These two cases are surely representative of just how difficult and complex the current landscape for patent prosecution and litigation is right now in the biosimilars markets and beyond. What is certainly clear is that while the threats are huge, the opportunities have never been greater for those who get their patent prosecution, protection, litigation, and commercialization strategies right.

The fourth annual MIP Life Sciences Forum brings together leading industry players, including in-house and outside counsel, and members of the judiciary, to address the latest decisions and tumultuous changes affecting the life sciences industry today. By attending, you will be able to benchmark your practices against those of your peers, and understand what you need to do to take advantage of the considerable opportunities available, while at the same time protecting your patents and minimising your risk.

Book your place today.
PROGRAMME

8.15 REGISTRATION AND COFFEE

9.00 OPENING REMARKS

Elizabeth Weiswasser, co-head, life sciences and patent litigation practices, Weil
Stephanie Donahue, senior director, patent litigation, Sanofi

9.10 The latest developments in patent prosecution and exclusivity extension

• Avoiding prosecution pitfalls in developing pharmaceutical patent portfolios
• Strategies to manage and extend market exclusivity
• Subject matter eligibility in life sciences – patenting discoveries, diagnostics, and therapies that may be deemed 'naturally occurring' by a patent examiner

9.20 PATENT TERM, PTA, AND ODP

• Recent developments in § 101 case law
• New pilot program for motions to amend
• Second update to PTAB Trial Practice Guide
• PTAB Precedential Opinion Panel (POP)
• Orange Book patent/biologic patent study and district court pharma litigation study

9.30 SPEAKERS

Carla Ji-Eun Kim, director, Sterne Kessler Goldstein & Fox (moderator)
Leon Lum, senior intellectual property counsel, legal & corporate affairs, Novo Nordisk
Cara Lowen, vice president and chief patent counsel, Codik BioSciences
Brian Walsh, assistant general counsel - intellectual property, Bristol Myers Squibb

9.40 The current patent landscape in Canada – an essential update

• The latest developments in the Canadian patent landscape, including:
  • Subject matter issues
  • File history estoppel
  • Patent term extensions
  • Pricing of patented medicines in Canada
  • How might these developments influence your patent strategy in Canada?

9.50 SPEAKERS

Jennifer Ledwell, associate, Marks & Clerk
William Coppola, intellectual property counsel, Aerie Pharmaceuticals

10.00 NETWORKING COFFEE BREAK

10.50 Analysing the latest developments affecting PTAB IPRs

• Orange Book patent/biologic patent study and district court pharma litigation study
• PTAB Precedential Opinion Panel (POP)
• Second update to PTAB Trial Practice Guide
• New pilot program for motions to amend

10.50 SPEAKERS

Michael Filibbert, partner, Finnegan (moderator)
Kristan Lansbery, director, patent attorney, Regeneron Pharmaceuticals
William Raich, partner, Finnegan

11.40 US pharma litigation: annual review and trends

• Recent developments in § 101 case law
• Momenta, estoppel, and other IPR-related litigation
• Patent term, PTA, and ODP

11.40 SPEAKERS

Keith Orso, partner, Irell & Manella
Jill Schmidt, senior counsel, Genentech
Ian Washburn, partner, Irell & Manella

12.30 NETWORKING LUNCH

13.20 Successful and practical strategies to adopt in cross-border litigation

This session highlights the particular problems posed by litigation in a cross-border context, and considers the strategies necessary to address and overcome these problems. Looking at real life instances and examples, delegates will gain an understanding of the best practices that need to be adopted to bring about a successful outcome.

13.20 SPEAKERS

Paul Inman, partner, Gowling WLG (moderator)
Paul Coletti, associate patent counsel, Johnson & Johnson
Ilya Goryachev, senior lawyer, Gorodissky

14.10 Misdeeds and major ramifications for patent litigation – a survey of recent case law relating to attorney’s fees and consequences of bad behavior during dealmaking, prosecution and litigation

This topic offers practical advice for prosecutors and litigators, along with a discussion of the tools available to remedy mistakes made or uncovered during diligence, and looks to answer key questions including:
• What types of litigation tactics are courts finding “exceptional” in the context of biopharmaceutical patent litigation?
• How can deal diligence upend a positive litigation outcome?
• How can litigation behavior taint in-house counsel patent prosecution efforts?
• How are companies evaluating and managing potentially inappropriate activities during patent prosecution?

14.10 SPEAKERS

Filko Prugo, partner, Ropes & Gray
Charlotte Jacobsen, partner, Ropes & Gray

15.00 NETWORKING COFFEE BREAK

15.20 Litigation management – best practice tips for successful collaborations

This session will look at the challenges involved in coordinating a successful litigation strategy. Looking from an in-house counsel perspective, delegates will gain an understanding of how best to prepare and work with outside counsel, including the matters that can be dealt with internally and what would be better outsourced.

15.20 SPEAKERS

Elizabeth Weiswasser, co-head, life sciences and patent litigation practices, Weil
Stephanie Donahue, senior director, patent litigation, Sanofi

16.10 An essential guide to commercialising your IP

• What are the main partnering issues to consider between large and small organizations?
• Working with competitors
• Investment - how to deal with funding from life sciences companies, whether US or from abroad, and funding from other sources (like NIH)

16.10 SPEAKERS

Chad Davis, partner, Dechert
Gloria Fuentes, executive director, corporate transactions, Merck
Michael Brignati, associate general counsel, Penn State University
Shaun Ryan, deputy general counsel, Moderna Therapeutics
Tom Rayski, partner, Dechert

17.00 CHAIR’S CLOSING REMARKS AND CONFERENCE ENDS
BOOKING FORM

| Early bird rate  | FREE | $795 |
| Standard rate | FREE | $1095 |

**METHOD OF PAYMENT**

Please tick the appropriate box to choose your payment method and sign below:

☐ Bank transfer (details will be provided by invoice)
☐ Credit card payment (pay online at www.managingip.com/MLifesciences or call +44 (0) 207 779 8811)

REGISTRATION: All registrations are subject to final review. Where the registration fee applies, the fee is charged in EUR.

PAYMENT: All registration fees (where applicable) must be received in full prior to the invoice due date or event date, whichever is sooner.

Please note that in completing this booking form you undertake to adhere to the cancellation and payment terms listed on this form.

Signature: Date: Position:

**MARKETING PREFERENCES**

I agree to receive exclusive news, content and offers from Managing IP and other Euromoney group companies and services by:

- Email
- Telephone
- Mail
- Third party (sponsors only)

You can unsubscribe at any time by clicking the “unsubscribe” link at the bottom of any communications we send you. You can also visit our preference centre and Privacy Notice.

**FINANCIAL AID POLICY**

Please refer to our website for the details on full or partial scholarship available for lawyers and law students experiences financial hardships.